advertisement
Abstract #25086 Published in IGR 12-1
Efficacy and Tolerability of Bimatoprost versus Travoprost in Patients Previously on Latanoprost: a 3-Month, Randomized, Masked-Evaluator, Multicenter Study
Kammer J; Katzman B; Ackerman S; Hollander DBritish Journal of Ophthalmology 2010; 94: 74-79
PURPOSE: To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue (PGA) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure (IOP) lowering while on latanoprost. METHODS: Prospective, randomised, investigator-masked, multicentre clinical trial. Patients on latanoprost 0.005% monotherapy requiring additional IOP lowering discontinued latanoprost and were randomised to bimatoprost 0.03% (n=131) or travoprost 0.004% (n=135). IOP was measured at latanoprost-treated baseline and after 1 and 3 months of replacement therapy. RESULTS: Baseline mean diurnal IOP on latanoprost was similar between groups. Mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 (p=0.009) and 3 months (p=0.024). Overall, 22.0% of bimatoprost patients vs 12.1% of travoprost patients achieved a >/=15% reduction in diurnal IOP from latanoprost-treated baseline at both months 1 and 3 (p=0.033). At month 3, the additional mean diurnal IOP reduction from latanoprost-treated baseline was 2.1 (95% CI: 1.7, 2.5) mm Hg (11.0%) with bimatoprost and 1.4 (95% CI: 0.9, 1.8) mm Hg (7.4%) with travoprost (p=0.024). At 3 months, 11.5% of bimatoprost and 16.5% of travoprost patients demonstrated a >/=1-grade increase in physician-graded conjunctival hyperaemia (p=0.288). Hyperaemia was reported as a treatment-related adverse event in 3.1% of bimatoprost and 1.5% of travoprost patients (p=0.445). CONCLUSION: Patients on latanoprost requiring lower IOP achieved greater additional short-term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost. Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost.
United States;
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
